Overview

Pharmacokinetics of BIBR 277 in Hypertensive Patients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The pharmacokinetic profile of BIBR 277 single dose given in capsule form to hypertensives was evaluated. The results of the present study are to be used in the Japanese population pharmacokinetics analysis
Phase:
Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Telmisartan